Zydus unit licenses experimental drug to treat rare rapid-ageing disease in children

Sentynl Therapeutics licensed Progerinin from PRG S&T for Hutchinson-Gilford Progeria Syndrome. Phase 2A trial data expected by 1H 2026. Zydus shares closed at ₹886.90.

Leave a Reply

Your email address will not be published. Required fields are marked *